<DOC>
	<DOCNO>NCT02798627</DOCNO>
	<brief_summary>NS2359 attenuate euphoria associate cocaine use . In manner parallel cocaine , NS2359 block reuptake dopamine ( DA ) , norepinephrine ( NE ) , serotonin ( 5HT ) nanomolar affinity 3 transporter . In primate NS2359 significantly attenuate cocaine self-administration . In several phase II clinical trial major depressive disorder adult attention deficit disorder , NS2359 cause euphoria . NS2359 exhibit abuse potential human laboratory study compare NS2359 amphetamine . In phase I human laboratory interaction study , NS2359 show toxicity 20 40 mg cocaine , attenuate reward cardiovascular effect intravenous cocaine . On basis promising study , investigator propose Phase II double-blind clinical trial NS2359 cocaine addiction ( CA ) . The propose trial involve 100 CA subject participate eight week trial , include 1-week baseline 8 week NS2359 placebo treatment . Four week complete medication phase , one follow-up visit . Subjects randomly assign treatment placebo 2 mg NS2359 daily , possible decrease 1 mg daily adverse event . This dose range select basis phase I II evidence tolerability NS2359 plasma level associate blockade cocaine reward . This project potential identify first effective pharmacotherapy CA .</brief_summary>
	<brief_title>Trial Of NS2359 For The Treatment Cocaine Dependence</brief_title>
	<detailed_description>In phase II randomize double-blind , placebo-controlled trial , 40 person randomize NS2359 40 placebo . The primary hypothesis : NS2359-treated subject ( compare placebo-treated subject ) achieve 3 consecutive week cocaine abstinence , measure urine benzoylecgonine ( BE ) assay , last three week trial . The study 9 week : one week screening , follow 8-week double-blind , placebo-controlled trial . All subject receive weekly cognitive behavioral therapy ( CBT ) encourage abstinence 3 time weekly clinic visit . Investigators expect ~ 20 % dropout rate , base recent CA clinical trial ( eg , Kampman et al , 2015 2013 ) , 80 randomize patient yield ~ 64 study completers . There 1 month start-up period , follow 20 month recruitment study . The 1 month start-up period allow train staff , preparation study capsule , placement study advertisement , etc . Penn IRB approval obtain . There 2-month termination period allow final patient complete study . Data cleaning , statistical analysis preparation report do final two month . Based recent cocaine pharmacotherapy trial conduct team , monthly enrollment ~4 CA participant ( respondent flyer advertisement ) feasible . Recruitment occur University Pennsylvania 's Treatment Research Center ( TRC ) , lead Kyle Kampman , MD , Wade Berrettini , MD , PhD , Professors Psychiatry Penn . At TRC , CA patient respondent advertisement free treatment CA . The ethnicity 90 % African-American , 9 % European-American , 70 % male , mean age 47 ( +/- 12 ) .</detailed_description>
	<mesh_term>Cocaine-Related Disorders</mesh_term>
	<mesh_term>Cocaine</mesh_term>
	<criteria>1 . Male female , 1865 year old . 2 . Meets diagnostic criterion ( DSMV ) current diagnosis cocaine use disorder , moderate severe , semistructured interview . 3 . In past 30 day , use less $ 100worth cocaine 4 . Speaks , understand , print English . 1 . Meets DSMV criterion substance use disorder , moderate severe , substance cocaine , alcohol nicotine . Subjects comorbid alcohol use disorder accept alcohol use disorder severe enough require medical alcohol detoxification . 2 . Needs treatment psychoactive medication ( exception diphenhydramine melatonin , necessary , sleep ) . 3 . Meets current lifetime DSMV criterion schizophrenia psychotic disorder , organic mental disorder . 4 . Has another Axis I psychiatric disorder opinion physician interfere completion study place patient heighten risk participation trial . 5 . Has evidence history significant hematological , pulmonary , endocrine , cardiovascular , renal gastrointestinal disease . 6 . Use investigational medication 30 day prior randomization . 7 . Is female positive pregnancy test , contemplate pregnancy next 6 month , nursing , use effective contraception ( relevant ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>